-
1دورية أكاديمية
المؤلفون: Makker V., Colombo N., Herráez A.C., Santin A.D., Colomba E., Miller D.S., Fujiwara K.
مصطلحات موضوعية: doxorubicin, lenvatinib, paclitaxel, pembrolizumab, programmed death 1 ligand 1, vasculotropin, adult, advanced cancer, cancer chemotherapy, cancer growth, cancer recurrence, cancer survival, drug efficacy, drug safety, endometrium cancer, febrile neutropenia, female, follow up, human, hypertension, major clinical study, mismatch repair, multicenter study, Note, phase 3 clinical trial, progression free survival, treatment duration
العلاقة: Journal of Bone and Joint Surgery; Diğer; https://doi.org/10.1097/OGX.0000000000001032Test; https://hdl.handle.net/11454/79666Test; 77; 275; 276
-
2دورية أكاديمية
المؤلفون: Makker V., Colombo N., Herráez A.C., Santin A.D., Colomba E., Miller D.S., Fujiwara K.
مصطلحات موضوعية: doxorubicin, lenvatinib, paclitaxel, pembrolizumab, programmed death 1 ligand 1, vasculotropin, adult, advanced cancer, cancer chemotherapy, cancer growth, cancer recurrence, cancer survival, drug efficacy, drug safety, endometrium cancer, febrile neutropenia, female, follow up, human, hypertension, major clinical study, mismatch repair, multicenter study, Note, phase 3 clinical trial, progression free survival, treatment duration
العلاقة: Journal of Bone and Joint Surgery; Diğer; 219355; https://doi.org/10.1097/OGX.0000000000001032Test; https://hdl.handle.net/11454/83953Test; 77; 275; 276; 2-s2.0-85130830880
-
3دورية أكاديمية
المؤلفون: Makker V., Colombo N., Herráez A.C., Santin A.D., Colomba E., Miller D.S., Fujiwara K.
مصطلحات موضوعية: doxorubicin, lenvatinib, paclitaxel, pembrolizumab, programmed death 1 ligand 1, vasculotropin, adult, advanced cancer, cancer chemotherapy, cancer growth, cancer recurrence, cancer survival, drug efficacy, drug safety, endometrium cancer, febrile neutropenia, female, follow up, human, hypertension, major clinical study, mismatch repair, multicenter study, Note, phase 3 clinical trial, progression free survival, treatment duration
العلاقة: Journal of Bone and Joint Surgery; Diğer; https://doi.org/10.1097/OGX.0000000000001032Test; https://hdl.handle.net/11454/79666Test; 77; 275; 276; 2-s2.0-85130830880
-
4دورية أكاديمية
المؤلفون: Cescon D.W., Cortes J., Rugo H.S., Nowecki Z., Im S.-A., Yusof M.M., Gallardo C.
مصطلحات موضوعية: carboplatin, alanine aminotransferase, gemcitabine, paclitaxel, pembrolizumab, placebo, programmed death 1 ligand 1, sodium chloride, antineoplastic agent, CD274 protein, human, immunological antineoplastic agent, monoclonal antibody, adult, age distribution, alopecia, anemia, Article, cancer adjuvant therapy, cancer combination chemotherapy, cancer immunotherapy, cancer patient, cancer recurrence, cancer survival, clinical outcome, colitis, controlled study, double blind procedure, drug efficacy, drug safety
العلاقة: The Lancet; Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı; https://hdl.handle.net/11454/79608Test; https://doi.org/10.1016/S0140-6736Test(20)32531-9; 396; 10265; 1817; 1828
الإتاحة: https://doi.org/10.1016/S0140-6736Test(20)32531-9
https://hdl.handle.net/11454/79608Test -
5دورية أكاديمية
المؤلفون: Cortes J., Cescon D.W., Rugo H.S., Nowecki Z., Im S.-A., Yusof M.M., Gallardo C.
مصطلحات موضوعية: alanine aminotransferase, carboplatin, gemcitabine, paclitaxel, pembrolizumab, placebo, programmed death 1 ligand 1, sodium chloride, antineoplastic agent, CD274 protein, human, immunological antineoplastic agent, monoclonal antibody, adult, age distribution, alopecia, anemia, Article, cancer adjuvant therapy, cancer combination chemotherapy, cancer immunotherapy, cancer patient, cancer recurrence, cancer survival, clinical outcome, colitis, controlled study, double blind procedure, drug efficacy, drug safety
العلاقة: The Lancet; Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı; https://doi.org/10.1016/S0140-6736Test(20)32531-9; https://hdl.handle.net/11454/79608Test; 396; 10265; 1817; 1828; 2-s2.0-85097177716
الإتاحة: https://doi.org/10.1016/S0140-6736Test(20)32531-9
https://hdl.handle.net/11454/79608Test